PICO Portalanswers from OpenAlex & ORCID
Bart J. F. van den Bemt
ResearcherPublications, citations & collaboration network
Bart J. F. van den Bemt is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Bart J. F. van den Bemt have?
PICO Portalindexed works
Bart J. F. van den Bemt has 306 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bart J. F. van den Bemt have?
PICO Portalcitation count
Bart J. F. van den Bemt has 6,051 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Bart J. F. van den Bemt?
PICO Portalh-index
Bart J. F. van den Bemt has an h-index of 42 in OpenAlex.
What is the i10-index of Bart J. F. van den Bemt?
PICO Portali10-index
Bart J. F. van den Bemt has an i10-index of 134 in OpenAlex.
What is the ORCID of Bart J. F. van den Bemt?
PICO Portalorcid
The ORCID for Bart J. F. van den Bemt is on the source record.
What is the OpenAlex record for Bart J. F. van den Bemt?
PICO Portalopenalex
The OpenAlex for Bart J. F. van den Bemt is on the source record.
What are the most-cited papers on Bart J. F. van den Bemt?
PICO Portalmost cited works
Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature
Bart J. F. van den Bemt, Hanneke Zwikker, Cornelia HM van den Ende
Prevalence and Preventability of Drug‐Related Hospital Readmissions: A Systematic Review
Najla El Morabet, Elien B. Uitvlugt, Bart J. F. van den Bemt, Patricia M. L. A. van den Bemt, Marjo J. A. Janssen, Fatma Karapinar‐Çarkit
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
Noortje van Herwaarden, Aatke van der Maas, M.J.M. Minten, F.H.J. van den Hoogen, Wietske Kievit, Ronald van Vollenhoven, J. W. J. Bijlsma, Bart J. F. van den Bemt, Alfons A den Broeder
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab
Lieke Tweehuysen, Bart J. F. van den Bemt, Iris L. van Ingen, Alphons J.L. de Jong, W.H. van der Laan, F.H.J. van den Hoogen, Alfons A den Broeder
Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs
Bart J. F. van den Bemt, F.H.J. van den Hoogen, B. Benraad, Yechiel A. Hekster, Piet L. C. M. van Riel, Wim van Lankveld